Yes, it is also a good possibility and maybe Stamler wants to inform the main news even if he does not know the result of the randomized study. His talk is about alpha-synuclein. The effect of it has been told in several ATH434 studies both in MSA and PD animal models and now they also have info on it in the open study. So it is perhaps easy to make some comments about the hypothesis of this randomized study (A Phase 2 Study of ATH434, a Novel Inhibitor of α-synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA)).
AAN conference new data predictions, page-4
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.789K | 559.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 71154557 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 22151480 | 14 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 657376 | ||
| Last updated 12.27pm 03/06/2024 ? | |||||
| ATH (ASX) Chart |